UK diagnostics firm DNA Electronics presented data supporting its LiDia‑SEQ rapid sequencing platform and said it plans commercialization in 2027, targeting same‑day infectious-disease and cancer testing. The fully automated, cartridge-based system uses semiconductor sequencing (a technology related to Ion Torrent) and on‑instrument basecalling to identify pathogens and antimicrobial resistance markers from whole blood in hours. Poster data showed the prototype could detect bloodstream pathogens down to very low loads and identify resistance signatures without culture, enabling clinicians to target antibiotics within a single day. DNAe positions LiDia‑SEQ for sepsis and oncology applications where speed and actionable molecular detail can change clinical decision-making. The company emphasized automation, minimal hands‑on time, and integration of sample prep and targeted capture to speed turnaround—key attributes for hospital and near‑patient deployment.